Inhibition of Ras attenuates the course of experimental autoimmune neuritis

Michal Kafri, Yoel Kloog, Amos D. Korczyn, Ramona Ferdman-Aronovich, Vivian Drory, Aviva Katzav, Itzhak Wirguin, Joab Chapman

Research output: Contribution to journalArticlepeer-review


EAN induced in Lewis rats by immunization with peripheral bovine myelin was treated by the Ras inhibitor farnesylthiosalicylate (FTS). Treatment from day 0 with FTS (5 mg/kg intraperitoneally twice daily) attenuated peak clinical scores (mean ± S.E., 2.5 ± 0.5 compared to 4.1 ± 0.5 in saline treated controls, p = 0.018, t-test) but not recovery. Treatment from day 10 with FTS attenuated peak disability (2.5 ± 0.6, p = 0.032 compared to saline treated controls) and improved recovery (0.84 ± 0.42, untreated controls 2.4 ± 0.6, p = 0.028 by repeated measures ANOVA). Effects were confirmed by rotarod and nerve conduction studies. An inactive analogue, geranylthiosalicylate, had no clinical effect. Inhibition of Ras is of potential use in the treatment of inflammatory neuropathies.

Original languageEnglish
Pages (from-to)46-55
Number of pages10
JournalJournal of Neuroimmunology
Issue number1-2
StatePublished - Nov 2005
Externally publishedYes

Bibliographical note

Funding Information:
This study was supported by the Bircher–Benner Fund founded by Dr. Abraham Avrech, the Sieratzki Chair of Neurology, Tel Aviv University and Thyreos Inc, Newark, NJ, USA.


  • Experimental autoimmune neuritis
  • Farnesylthiosalicylate
  • Guillain-Barré syndrome
  • Nerve conduction
  • Ras
  • Rat

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Inhibition of Ras attenuates the course of experimental autoimmune neuritis'. Together they form a unique fingerprint.

Cite this